Therapeutic | Toripalimab |
Target | PDCD1 |
Heavy Chain | QGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGITTVATTYYWYFDVWGQGTTVTVSS |
Light Chain | DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK |
100% seqID Fv Structure | 6jbt [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6jbt [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2018 |
INN Year Recommended | 2019 |
Companies Involved | Fudan University, Peking University, Shanghai Junshi Biosciences, Sun Yat-Sen University |
Conditions Approved | Malignant melanoma |
Conditions Active | Nasopharyngeal cancer, Oesophageal cancer, Biliary cancer, Gastric cancer, Non-small cell lung cancer, Solid tumours, Urogenital cancer, Head and neck cancer, Alveolar soft part sarcoma, Breast cancer, Cancer, Liver cancer, Lymphoma, Neuroendocrine tumours, Renal cancer |
Conditions Discontinued | na |
Notes |